Leeza Osipenko, PhD

CEO

Leeza gained experience in academia, consulting and public sector before establishing Consilium Scientific in 2020. After completing PhD in Systems Engineering in the USA, she came to England. Her career started at the University of Warwick Medical School where she worked as Senior Research Fellow on evaluating non-invasive foetal DNA tests. Then she relocated to London and joined a consulting company as Principal Economist leading on projects for NICE and other UK public sector departments. Leeza is an expert in Health Technology Assessment and between 2014 and 2018 she served as a Director of NICE Scientific Advice. Her academic work focuses on examining the status quo of clinical research, through quality improvement, transparency, and methodological rigour. In particular, she is interested in clinical data integrity, health policy, applied clinical research, and clinical trial design. Between 2018 and 2021 Leeza was a Senior Lecturer in Practice at the London School of Economics (LSE) Department of Health Policy and currently she is a Senior Visiting Fellow at LSE Health. Leeza serves on the Board of Directors at HealthSenseUK and ISRCTN.

Ekaterina Cleary, PhD

Data Scientist

Dr. Ekaterina Cleary holds a PhD in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell and a Master's Degree in Bioinformatics from Boston University. Her PhD thesis examined the genetic and environmental determinants of Alzheimer’s disease progression. Ekaterina completed her postdoctoral studies at the Center for Integration of Science and Industry at Bentley University, where she is best known for quantifying the substantial contribution of federal grant funding (i.e. National Institutes of Health) towards pharmaceutical drug discovery. With prior experience in academia and consulting, her current work sits at the intersection of health policy, evidence evaluation, and medical reimbursement. At Consilium Scientific, she leads the development of Evimeter, a quantitative framework that evaluates the strength of clinical evidence supporting breakthrough medical devices and diagnostics.

Andrea Caputo Svensson, PhD

RareCare – Project Manager

Andrea holds a PhD in Marine Ecology from Stockholm University (Sweden), where he specialized as Molecular Microbiologist, and a MSc in Marine Biology from the Polytechnic University of Marche (Italy). After graduating PhD, he joined the Stockholm International Water Institute working as Programme Officer on policy issues related to antimicrobial resistance (AMR) and its threat to public health and the achievement of the Sustainable Development Goals of the Agenda 2030. Andrea has also worked as Expert Consultant for the Food and Agriculture Organization of the United Nations on the (lack of) implementation of the AMR National Action Plans and the key role of the aquaculture sector for the global food safety and security. Currently, Andrea also covers the position of Global Health Advisor at ReAct – Action on Antibiotic Resistance, where he is responsible for a wide portfolio of antibiotic resistance policy dialogues, including cancer care treatment, access to effective antibiotics, and community engagement..

Jack Lewis

Analyst

Jack joined the Consilium Scientific team in January 2024. He graduated with an MSc in Natural Sciences at the University of Exeter in 2020, gaining hands-on experience with medical diagnostic tools. After training as an accountant for a year he decided to pivot back to a more research-focused role. His main interests are health inequity and the impact of health policy on the global scale, especially in the global south.

Scott Lewis

Scott joined Consilium Scientific as an intern in August 2022, after gaining a first class bachelor’s degree in Biological Sciences from the University of Exeter. In addition to managing Consilium's administrative tasks, his role involves developing social media strategy, coordinating the seminar programme, and collaborating on research projects in clinical trials transparency. Scott is continuing to pursue his interest in health policy and clinical trial transparency and plans to gain more experience within real world research, further understanding where issues within health policy lie internationally, particularly through data visualisation.

Howard Loree, PhD

Dr. Howard Loree has diverse research & development experience in the medical device industry including highly innovative surgical and interventional products for mechanical circulatory support, vascular access, peripheral vascular, neurovascular, aesthetic medicine, spine, and ophthalmology applications.

Dr. Loree has hands-on aptitude across the complete product development life cycle with an emphasis on cardiovascular, where he has deep expertise in developing complex electromechanical devices for ventricular assist device (VAD) and other applications.

At both startup and growth stage companies, Dr. Loree has proven his ability to recruit, lead, mentor, and build exceptional cross-functional development teams. As a project manager he has developed highly productive relationships with external partners and is accustomed to meeting aggressive goals.

Dr. Loree’s personal technical accomplishments include raising over $4.5M in NIH funding for medical device development; planning, executing, and reporting preclinical studies to rapidly establish in vitro and in vivo feasibility; supporting successful FDA submissions including IND, IDE, HDE, 510(k), and PMA; supporting law firms and medical device manufacturers with post-market regulatory/compliance inquiries, recalls, and product liability litigation; and performing technology due diligence for venture capital investors.

Dr. Loree’s education includes B.S. and M.S. degrees in Mechanical Engineering from MIT as well as a Ph.D. in Medical Engineering from the Harvard‐MIT Division of Health Sciences and Technology. He also completed a postdoctoral research fellowship in cardiovascular biomechanics at Brigham and Women’s Hospital, Harvard Medical School.